

Prescription Pharmaceutical Products¹

PRODUCT	INDICATION	TERRITORY					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi®	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Q1-24	●	●	Q1-25	Incyte
Minjuvi®	Relapsed or refractory follicular lymphoma (FL)		▲	▲	▲	▲	Incyte
Pemazyre®	Metastatic cholangiocarcinoma		■	●	●	■	Incyte
Akynzeo®	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Q4-22	Q3-22	Q3-22			Helsinn
Aloxi® / Onicit®	Prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy	Q4-22	Q1-25			Q1-25	Helsinn
Tavalisse®	Treatment of chronic immune thrombocytopenia		●	●	●	■	Rigel
Trelstar®	Advanced prostate cancer	Q2-20					Debiopharm
Vidaza®	Myelodysplastic syndrome		Q2-10				BMS
Abraxane®	Metastatic pancreatic cancer		Q4-17				BMS
Halaven®	Metastatic breast cancer and soft tissue sarcoma		Q4-17	Q4-19	Q2-22		Eisai
Lenvima®	Differentiated thyroid cancer and unresectable hepatocellular carcinoma		Q4-17		Q1-22		Eisai
Lenvima®	Advanced renal cell cancer		Q4-17				Eisai
BGx							
Ladevina® (lenalidomide)	Multiple myeloma; myelodysplastic syndrome			2011	Q3-19		Own
Ladevina® (lenalidomide)	Mantle Cell Lymphoma; follicular lymphoma			2011			Own
Zyvalix® (abiraterone)	Metastatic prostate cancer			2014	Q2-18		Own
Karfib® (carfilzomib)	Relapsed or refractory multiple myeloma			Q4-19	■		Own
Leprid® (leuprolide)	Palliative treatment of advanced prostate cancer			2007			Own
Rembre® (dasatinib)	Chronic myeloid leukemia			2013	Q1-22		Own
Palbocil®, Bapocil® (palbociclib)	Breast cancer			Q1-23	●		Own
Xetrane® (pomalidomide)	Multiple myeloma			Q2-19	●		Own
Xetrane® (pomalidomide)	AIDS-related Kaposi sarcoma			Q2-22			Own

¹ See MD&A for more details.

▲ Pre-registration: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.

● Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.

■ Approved: Approved by regulatory authorities but not yet commercially launched.



Prescription Pharmaceutical Products¹

PRODUCT	INDICATION	TERRITORY					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Infectious Diseases							
Ambisome®	Invasive fungal infection	—	1997	—	—	—	Gilead
Cresemba®	Invasive fungal infection	—	Q2-20	Q3-19	Q3-19	Q2-19	Basilea
Impavido®	Leishmaniasis						Own
BGx							
Dolufevir® (dolutegravir)	HIV infection			Q2-21			Own
Other Specialty							
Exelon®	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Q2-21	Q2-21	Q2-21	Q2-21	Q2-21	Own
Ibsrela®	IBS-C	Q1-21	—	—	—	—	Ardelyx
Salofalk®	Ulcerative colitis	—	—	2007	Pre-2019	—	Dr. Falk
Ursofalk®	Primary biliary cirrhosis	—	—	2007	Pre-2019	—	Dr. Falk
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24	—	—	—	—	TXMD
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24	—	—	—	—	TXMD
BGx							
Fibridoner® (pirfenidone)	Idiopathic pulmonary fibrosis			2017			Own

¹ See MD&A for more details.



Pipeline and Products in Early Launch Stage¹

Product	Indication or Therapeutic Area	Territory					Expected Launch Year
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi®	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Q1-24	●	●	Q1-25	2025-2026
Minjuvi®	Relapsed or refractory follicular lymphoma (FL)		▲	▲	▲	▲	2027
Pemazyre®	Metastatic cholangiocarcinoma		■	●	●	■	2025-2026
Tavalisse®	Treatment of chronic immune thrombocytopenia		●	●	●	■	2025-2026
Bapocil® ¹	Breast Cancer				●		2025
Xetrane® ¹	Multiple myeloma				●		2025
Rembre® ¹	Chronic myeloid leukemia				Q1-22		—
O501 ¹	Oncology/Hematology			●			2025
O502 ¹	Oncology/Hematology			●			2025
O401	Oncology/Hematology		◆				2027-2028
H403	Oncology/Hematology		◆		◆		2027-2028
H402	Oncology/Hematology		◆		◆		2028-2029
Other Specialty							
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24					—
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24					—
Crexont®	Parkinson's disease	▲	▲	▲	▲	▲	2027-2028
Qelbree™	Attention-Deficit Hyperactivity Disorder (ADHD)	●					2026-2027
Jornay PM™	Attention-Deficit Hyperactivity Disorder (ADHD)	■	▲			▲	2025-2028
C401 (Neurology)	Other Specialty				●		2025-2026
C402/403 (Neurology)	Other Specialty		●			▲	2026-2027

¹ See MD&A for more details.

◆ Development: Products under development stage.

▲ Pre-registration: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.

● Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.

■ Approved: Approved by regulatory authorities but not yet commercially launched.